157 related articles for article (PubMed ID: 37211453)
21. Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.
Gunale B; Kapse D; Kar S; Bavdekar A; Kohli S; Lalwani S; Meshram S; Raut A; Kulkarni P; Samuel C; Munshi R; Gupta M; Plested JS; Cloney-Clark S; Zhu M; Pryor M; Hamilton S; Thakar M; Shete A; Dharmadhikari A; Bhamare C; Shaligram U; Poonawalla CS; Mallory RM; Glenn GM; Kulkarni PS;
JAMA Pediatr; 2023 Jul; 177(9):911-20. PubMed ID: 37523166
[TBL] [Abstract][Full Text] [Related]
22. Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Kelly E; Greenland M; de Whalley PCS; Aley PK; Plested EL; Singh N; Koleva S; Tonner S; Macaulay GC; Read RC; Ramsay M; Cameron JC; Turner DPJ; Heath PT; Bernatoniene J; Connor P; Cathie K; Faust SN; Banerjee I; Cantrell L; Mujadidi YF; Belhadef HT; Clutterbuck EA; Anslow R; Valliji Z; James T; Hallis B; Otter AD; Lambe T; Nguyen-Van-Tam JS; Minassian AM; Liu X; Snape MD;
J Infect; 2023 Sep; 87(3):230-241. PubMed ID: 37331429
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
Shinde V; Bhikha S; Hoosain Z; Archary M; Bhorat Q; Fairlie L; Lalloo U; Masilela MSL; Moodley D; Hanley S; Fouche L; Louw C; Tameris M; Singh N; Goga A; Dheda K; Grobbelaar C; Kruger G; Carrim-Ganey N; Baillie V; de Oliveira T; Lombard Koen A; Lombaard JJ; Mngqibisa R; Bhorat AE; Benadé G; Lalloo N; Pitsi A; Vollgraaff PL; Luabeya A; Esmail A; Petrick FG; Oommen-Jose A; Foulkes S; Ahmed K; Thombrayil A; Fries L; Cloney-Clark S; Zhu M; Bennett C; Albert G; Faust E; Plested JS; Robertson A; Neal S; Cho I; Glenn GM; Dubovsky F; Madhi SA;
N Engl J Med; 2021 May; 384(20):1899-1909. PubMed ID: 33951374
[TBL] [Abstract][Full Text] [Related]
24. Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines.
Marchese AM; Kalkeri R; Vadivale M; Suntronwong N; Toback S; Poovorawan Y
Expert Rev Vaccines; 2023; 22(1):620-628. PubMed ID: 37386785
[TBL] [Abstract][Full Text] [Related]
25. A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
Kulkarni PS; Gunale B; Kohli S; Lalwani S; Tripathy S; Kar S; Raut S; Kulkarni P; Apte A; Bavdekar A; Bhalla HL; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Pryor M; Hamilton S; Thakar M; Sannidhi RS; Baranwal P; Bhamare C; Dharmadhikari A; Gupta M; Poonawalla CS; Shaligram U; Kapse D;
Sci Rep; 2023 Oct; 13(1):16579. PubMed ID: 37789040
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
Heath PT; Galiza EP; Baxter DN; Boffito M; Browne D; Burns F; Chadwick DR; Clark R; Cosgrove C; Galloway J; Goodman AL; Heer A; Higham A; Iyengar S; Jamal A; Jeanes C; Kalra PA; Kyriakidou C; McAuley DF; Meyrick A; Minassian AM; Minton J; Moore P; Munsoor I; Nicholls H; Osanlou O; Packham J; Pretswell CH; San Francisco Ramos A; Saralaya D; Sheridan RP; Smith R; Soiza RL; Swift PA; Thomson EC; Turner J; Viljoen ME; Albert G; Cho I; Dubovsky F; Glenn G; Rivers J; Robertson A; Smith K; Toback S;
N Engl J Med; 2021 Sep; 385(13):1172-1183. PubMed ID: 34192426
[TBL] [Abstract][Full Text] [Related]
27. NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.
Marchese AM; Zhou X; Kinol J; Underwood E; Woo W; McGarry A; Beyhaghi H; Áñez G; Toback S; Dunkle LM
Vaccine; 2023 May; 41(22):3461-3466. PubMed ID: 37127523
[TBL] [Abstract][Full Text] [Related]
28. Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial.
Áñez G; Dunkle LM; Gay CL; Kotloff KL; Adelglass JM; Essink B; Campbell JD; Cloney-Clark S; Zhu M; Plested JS; Roychoudhury P; Greninger AL; Patel N; McGarry A; Woo W; Cho I; Glenn GM; Dubovsky F;
medRxiv; 2022 Sep; ():. PubMed ID: 36172135
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
31. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
32. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T;
Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G
Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209
[TBL] [Abstract][Full Text] [Related]
34. Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study.
Kim HK; Park SK; Choe SA; Gwak ES; Cowling BJ; Kim YM; Lee KH; Lee SW; Kwon GY; Jang EJ; Kim RK; Choe YJ; Kwon D
Vaccine; 2024 Mar; 42(7):1440-1444. PubMed ID: 38365479
[TBL] [Abstract][Full Text] [Related]
35. Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
Fix J; Christopher Mast T; Smith K; Baker N
Vaccine; 2024 Apr; 42(9):2161-2165. PubMed ID: 38494410
[TBL] [Abstract][Full Text] [Related]
36. Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19.
Mateo-Urdiales A; Sacco C; Petrone D; Bella A; Riccardo F; Del Manso M; Bressi M; Siddu A; Brusaferro S; Palamara AT; Rezza G; Pezzotti P; Fabiani M;
JAMA Netw Open; 2023 Oct; 6(10):e2336854. PubMed ID: 37792377
[TBL] [Abstract][Full Text] [Related]
37. Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine.
Follmann D; Mateja A; Fay MP; Magaret CA; Huang Y; Fong Y; Angier H; Nason M; Gay CL; Kotloff K; Woo W; Cho I; Dunkle LM
Clin Infect Dis; 2024 Feb; ():. PubMed ID: 38372392
[TBL] [Abstract][Full Text] [Related]
38. Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants.
Parums DV
Med Sci Monit; 2022 Mar; 28():e936523. PubMed ID: 35228506
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial.
Bennett C; Rivers EJ; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; Pardey TM; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Buchanan A; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM
J Infect Dis; 2023 Nov; ():. PubMed ID: 37970668
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
